Drug intelligence / Profile preview

carmustine + dacarbazine

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of carmustine (BCNU) and dacarbazine (DTIC). This combination is an antineoplastic treatment primarily studied for advanced melanoma. Carmustine is an alkylating agent that acts as a cell-cycle phase nonspecific antineoplastic medication, while dacarbazine is an antineoplastic agent with significant activity against melanomas. The combination is often used with additional agents such as cisplatin and tamoxifen in clinical trials.

Targets

DNA

Beyond the preview

Go deeper on carmustine + dacarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carmustine + dacarbazine.

Explore the full profile